Protein analysis and diagnostics firm Protagen announced this week that it has signed a cooperation contract with Bayer Schering Pharma AG for the discovery of novel biomarkers in endometriosis.

The company will explore the use of its UNIarray protein chip technology for the discovery of autoantibody patterns that are predictive of the disease.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.